Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 5
研究概览
简要总结
The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors. The trial consists ot two separate studies; CORGI-U in patients with stomach- bile ducts- gallbladder and pancreas cancer, and CORGI-L in patients with colorectal cancer.
CORGI-U will be designed as a phase-I-II-study,in which the first part will be a chemotherapy dose finding study, followed by a phase II part to establish response rates. All subjects receives radiotherapy concommitant.
CORGI-L is a phase II trial, in which patients are treated with chemotherapy at fixed doses with radiotherapy concommitant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Over 18 years of age
- •Measurable disease according to RECIST
- •ECOG Performance Status 0-1
- •ANC over 1.5 x 10 9/L
- •Platelets over 100 x 10 9/L
- •Creatinine less than 1.5 x ULN
- •Bilirubin less than 1.5 x ULN
- •ALT less than 2.5 x ULN
- •Signed informed concent
排除标准
- •Prior radiotherapy to the same local
- •Prior chemotherapy for locally advanced or metastatic disease
- •Pregnancy or breast feeding
- •Peripheral neuropathy more than grade 1
- •Uncontrolled diarrhéa
- •Other serious uncontrolled concomitant illness
- •Lymph node metastasis that can not be included in the GTV (gross tumor volume), without exceeding the stipulated radiotherapy doses in organs at risk
研究组 & 干预措施
Chemoradiotherapy
干预措施: oxaliplatin, capecitabine, radiotherapy (Other)